These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 26279333)

  • 21. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
    Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
    Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy.
    Regnery C; Kornblum C; Hanisch F; Vielhaber S; Strigl-Pill N; Grunert B; Müller-Felber W; Glocker FX; Spranger M; Deschauer M; Mengel E; Schoser B
    J Inherit Metab Dis; 2012 Sep; 35(5):837-45. PubMed ID: 22290025
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of bilateral ptosis on higher dose enzyme replacement therapy in Pompe disease.
    Yanovitch TL; Casey R; Banugaria SG; Kishnani PS
    J Neuroophthalmol; 2010 Jun; 30(2):165-6. PubMed ID: 20404746
    [No Abstract]   [Full Text] [Related]  

  • 24. Quantification of muscle pathology in infantile Pompe disease.
    Schänzer A; Kaiser AK; Mühlfeld C; Kulessa M; Paulus W; von Pein H; Rohrbach M; Viergutz L; Mengel E; Marquardt T; Neubauer B; Acker T; Hahn A
    Neuromuscul Disord; 2017 Feb; 27(2):141-152. PubMed ID: 27927596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial.
    Diaz-Manera J; Kishnani PS; Kushlaf H; Ladha S; Mozaffar T; Straub V; Toscano A; van der Ploeg AT; Berger KI; Clemens PR; Chien YH; Day JW; Illarioshkin S; Roberts M; Attarian S; Borges JL; Bouhour F; Choi YC; Erdem-Ozdamar S; Goker-Alpan O; Kostera-Pruszczyk A; Haack KA; Hug C; Huynh-Ba O; Johnson J; Thibault N; Zhou T; Dimachkie MM; Schoser B;
    Lancet Neurol; 2021 Dec; 20(12):1012-1026. PubMed ID: 34800399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enzyme replacement therapy induces T-cell responses in late-onset Pompe disease.
    Banati M; Hosszu Z; Trauninger A; Szereday L; Illes Z
    Muscle Nerve; 2011 Nov; 44(5):720-6. PubMed ID: 21952916
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early higher dosage of alglucosidase alpha in classic Pompe disease.
    Spada M; Pagliardini V; Ricci F; Biamino E; Mongini T; Porta F
    J Pediatr Endocrinol Metab; 2018 Dec; 31(12):1343-1347. PubMed ID: 30433875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Avalglucosidase alfa: First Approval.
    Dhillon S
    Drugs; 2021 Oct; 81(15):1803-1809. PubMed ID: 34591286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 24-months results in two adults with Pompe disease on enzyme replacement therapy.
    Vielhaber S; Brejova A; Debska-Vielhaber G; Kaufmann J; Feistner H; Schoenfeld MA; Awiszus F
    Clin Neurol Neurosurg; 2011 Jun; 113(5):350-7. PubMed ID: 21477922
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Enzyme replacement therapy with alglucosidase alfa in a late-onset Pompe disease patient during pregnancy.
    Oliveira Santos M; Evangelista T; Conceição I
    Neuromuscul Disord; 2018 Nov; 28(11):965-968. PubMed ID: 30314719
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
    Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
    Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case.
    Kobayashi H; Shimada Y; Ikegami M; Kawai T; Sakurai K; Urashima T; Ijima M; Fujiwara M; Kaneshiro E; Ohashi T; Eto Y; Ishigaki K; Osawa M; Kyosen SO; Ida H
    Mol Genet Metab; 2010 May; 100(1):14-9. PubMed ID: 20202878
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pompe disease: dramatic improvement in gastrointestinal function following enzyme replacement therapy. A report of three later-onset patients.
    Bernstein DL; Bialer MG; Mehta L; Desnick RJ
    Mol Genet Metab; 2010; 101(2-3):130-3. PubMed ID: 20638881
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New therapeutic approaches for Pompe disease: enzyme replacement therapy and beyond.
    Kishnani PS; Beckemeyer AA
    Pediatr Endocrinol Rev; 2014 Sep; 12 Suppl 1():114-24. PubMed ID: 25345093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Respiratory function during enzyme replacement therapy in late-onset Pompe disease: longitudinal course, prognostic factors, and the impact of time from diagnosis to treatment start.
    Stockton DW; Kishnani P; van der Ploeg A; Llerena J; Boentert M; Roberts M; Byrne BJ; Araujo R; Maruti SS; Thibault N; Verhulst K; Berger KI
    J Neurol; 2020 Oct; 267(10):3038-3053. PubMed ID: 32524257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical insight meets scientific innovation to develop a next generation ERT for Pompe disease.
    Kishnani PS; Chien YH; Berger KI; Thibault N; Sparks S
    Mol Genet Metab; 2024; 143(1-2):108559. PubMed ID: 39154400
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infantile Pompe disease on ERT: update on clinical presentation, musculoskeletal management, and exercise considerations.
    Case LE; Beckemeyer AA; Kishnani PS
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):69-79. PubMed ID: 22252989
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Quantification of intramuscular fat in patients with late-onset Pompe disease by conventional magnetic resonance imaging for the long-term follow-up of enzyme replacement therapy.
    Lollert A; Stihl C; Hötker AM; Mengel E; König J; Laudemann K; Gökce S; Düber C; Staatz G
    PLoS One; 2018; 13(1):e0190784. PubMed ID: 29315315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pompe disease in Austria: clinical, genetic and epidemiological aspects.
    Löscher WN; Huemer M; Stulnig TM; Simschitz P; Iglseder S; Eggers C; Moser H; Möslinger D; Freilinger M; Lagler F; Grinzinger S; Reichhardt M; Bittner RE; Schmidt WM; Lex U; Brunner-Krainz M; Quasthoff S; Wanschitz JV
    J Neurol; 2018 Jan; 265(1):159-164. PubMed ID: 29181627
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa.
    Lipinski SE; Lipinski MJ; Burnette A; Platts-Mills TA; Wilson WG
    Mol Genet Metab; 2009 Nov; 98(3):319-21. PubMed ID: 19640753
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.